

Fax completed form to Timiskaming Health Units Confidential Fax 705-647-5779 All information must be filled out for each vaccine ordered.

***If multiple doses are required of Refer to the Current Publicly Fo				
High Risk Immunization Reporting In	formation mu	st be completed and faxe	ed following vaccine administration	
Name of Facility, Physician, or Practice:				
Date:	Phone Number:		Fax Number:	
CLIENT NAME:	DOB:		PHONE:	
PERMANENT ADDRESS & POSTAL CODE:				
MENINGOCOCCAL C-ACYW135		HR Eligibility – Age 9 mont	hs to 55 and ≥ 56 years with:	
Name (First O. Last)		(please check all that apply)		
Name (First & Last):		□ Functional or anatom	nic asplenia	
DOB (YYYY/MM/DD):		Complement, properdin, factor D deficiency, or primary		
DATE ADMINISTERED:		antibody deficiency Cochlear implant recipient (pre/post implant)		
		☐ Acquired complement deficiencies (eg receiving eculizumab)		
Dose # 1 2 3 4 booster			, ,	
(see table- 15 of the Ontario Publicly funded Schedule for	number of eligible			
doses – please circle dose required)		Or School Program:		
		☐ Grade 7 – 12 student	S	
HUMAN PAPILLOMAVIRUS (HPV-9)		Eligibility		
Name (First & Last):		_	e 7 students (who remain eligible to grade	
DOB (YYYY/MM/DD):		12)		
		☐ HR Program: Men who	have sex with men – ages 9 – 26 Years	
DATE ADMINISTERED:				
☐ Two-Dose Series (Immunocompetent Age	9 – 14 yrs)	Note: Individuals who ha	ve completed their HPV4 series as of March 14,	
Note: In healthy individuals 15 years of age a		2019 will be considered up to date and not eligible for Publicly Funded		
received the first dose between 9 to less than 15 years of age, a 2-dose schedule can be used		HPV9 vaccine; For those completing an initiated HPV 4 series with HPV9; Full protection against the additional five strains will not be achieved. If		
		these individuals wish to b	be vaccinated with a complete series of HPV9	
☐ Three-Dose Series (Immunocompromised and immunocompetent HIV-infected individuals or those age ≥		they will need to purchase the addition HPV9 doses.		
15 yrs in grade 7-12)	3			
Dose # 1 2 3 (please circle dose re	quired)			



HAEMOPHILUS INFLUENZAE TYPE B (ACT-HIB®)	HR Eligibility - ≥ 5 years with: (please check all that apply)
Name (First & Last):	☐ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses)
DOR (VVVV NANA /DD):	☐ Functional or anatomic asplenia (1 dose)
DOB (YYYY/MM/DD):	☐ Immunocompromised related to disease or therapy (1 dose)
DATE ADMINISTERED:	☐ Bone marrow or solid organ transplant recipient (1 dose)
	☐ Lung transplant recipient (1 dose)
Dose # 1 2 3 (please circle dose required)	□ Cochlear implant recipient (pre/post implant) (1 dose)
* HSCT recipients are eligible for 3 doses. All other eligible conditions receive only 1 dose. See current Publicly Funded Immunization Schedule for	□ Primary antibody deficiency (1 dose)
vaccine intervals.	Note: High risk children 5 to 6 years of age who require DTaP-IPV and Hib should receive DTaP-IPV-Hib instead of Hib
MENINGOCOCCAL B Name (First & Last):	Eligibility – Age 2 months to 17 years with: (please check all that apply)
	☐ Functional or anatomic asplenia
DOB (YYYY/MM/DD):	☐ Complement, properdin, factor D deficiency, or primary antibody
DATE ADMINISTERED:	deficiencies
DATE ADMINISTERED.	☐ Cochlear implant recipient (pre/post implant)
Current Dose # 1 2 3 4	☐ Acquired complement deficiencies (eg receiving eculizumab)
	□ HIV
(see table 14 of the Ontario Publicly funded Schedule for number of eligible	
doses – please circle dose required)	
	UD EU-d-Wei
PNEUMOCOCCAL-C-13 VALENT (PREVNAR®13)	HR Eligibility: Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P-
•	HR Eligibility: Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a fourth dose of Pneumoccal-C-13
PNEUMOCOCCAL-C-13 VALENT (PREVNAR®13) Name (First & Last):	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13
•	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with:
Name (First & Last): DOB (YYYY/MM/DD):	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply)
Name (First & Last):	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with:
Name (First & Last): DOB (YYYY/MM/DD):	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses)
Name (First & Last): DOB (YYYY/MM/DD):	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Asplenia (anatomical or functional) (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED:	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) ☐ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) ☐ HIV (1 dose) ☐ Asplenia (anatomical or functional) (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Asplenia (anatomical or functional) (1 dose) □ Congenital immunodeficiencies involving any part of the immune
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a <u>fourth</u> dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Asplenia (anatomical or functional) (1 dose) □ Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Asplenia (anatomical or functional) (1 dose) □ Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) □ Immunocompromising therapy including use of long-term
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) □ Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	 Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P-23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) HIV (1 dose) Asplenia (anatomical or functional) (1 dose) Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic drugs (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Asplenia (anatomical or functional) (1 dose) □ Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) □ Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic drugs (1 dose) □ Malignant neoplasms including leukemia and lymphoma (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	 Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P-23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) HIV (1 dose) Asplenia (anatomical or functional) (1 dose) Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic drugs (1 dose) Malignant neoplasms including leukemia and lymphoma (1 dose) Sickle cell disease or other hemoglobinopathies (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P- 23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) □ Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) □ HIV (1 dose) □ Asplenia (anatomical or functional) (1 dose) □ Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) □ Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic drugs (1 dose) □ Malignant neoplasms including leukemia and lymphoma (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	 Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P-23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) HIV (1 dose) Asplenia (anatomical or functional) (1 dose) Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic drugs (1 dose) Malignant neoplasms including leukemia and lymphoma (1 dose) Sickle cell disease or other hemoglobinopathies (1 dose)
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 3 4	 Infants 6 weeks to 6 months of age who meet High Risk Pneumo-P-23 criteria should also receive a fourth dose of Pneumoccal-C-13 ≥ 50 years with: (please check all that apply) Hematopoietic stem cell transplant (HSCT) recipient* (3 doses) HIV (1 dose) Asplenia (anatomical or functional) (1 dose) Congenital immunodeficiencies involving any part of the immune system, including B-lympho-cyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (proper-din, or factor D deficiencies), or phagocytic functions (1 dose) Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, biologic and certain anti-rheumatic drugs (1 dose) Malignant neoplasms including leukemia and lymphoma (1 dose) Sickle cell disease or other hemoglobinopathies (1 dose)



PNEUMOCOCCAL-P-23 VALENT (PNEUMOVAX®23)	HR Eligibility – 2-64 years with: (please check all that apply)		
Name (First & Last):	 Chronic respiratory disease (<u>excluding</u> asthma, unless treated 		
	with high-dose corticosteroid therapy*)		
DOB (YYYY/MM/DD):	□ Chronic cardiac disease		
DATE ADMINISTERED:	□ Chronic cerebrospinal fluid leak		
DATE ADMINISTERED.	□ Cochlear implant recipients (pre/post implant)		
	$\hfill\Box$ Chronic neurologic condition that may impair clearance of oral		
Dose # 1 2*	secretions		
(please circle dose required)	□ Diabetes mellitus		
*For those <u>> 2</u> years of age, a 2 nd (one lifetime re-immunization)	☐ Resident of nursing home, home for the aged, chronic care		
dose should be given ≥5 years after the 1st dose for those	facility/ward		
meeting these specific High Risk Criteria and (see * on right)	☐ Chronic liver disease (including hepatitis B and C)		
A 2^{nd} dose should also be given at ≥ 65 years to anyone who	☐ Hepatic cirrhosis due to any cause*		
received the first dose prior to age 65 (5 year interval).	☐ Chronic renal disease or nephrotic syndrome*		
Please note: Pneumovax®23 utilized for routine immunizations	 Asplenia (functional or anatomical), splenic dysfunction* 		
may be used for this patient. If Pneumovax®23 is not normally	☐ Sickle-cell disease or other sickle cell haemoglobinopathy*		
stocked, please fill out this form accordingly. The High Risk Immunization Reporting Form must be completed and faxed to Timiskaming Health Unit following vaccine administration.	☐ Immunosuppressive therapy including use of long-term systemic corticosteroid, chemotherapy, radiation therapy, post-organ transplant therapy, certain anti-rheumatic drugs and other immunosuppressive therapy *		
	□ HIV*		
	 Undergoing solid organ or islet cell transplant (candidate or recipient) * 		
	□ Undergoing HSCT (candidate or recipient)*		
	□ Congenital (primary) immunodeficiency involving any part of the		
	immune system including B-lymphocyte (humoral) immunity, T-		
	lymphocyte (cell) mediated immunity, complement system (properdin,		
	or factor D deficiencies), or phagocytic functions *		
	☐ Malignant neoplasms including leukemia and lymphoma*		
Polio (IPV)	HR Eligibility > 18 years Travellers who have completed their		
IPV/Tdap-IPV	immunization series against polio and are travelling to areas where		
	poliovirus is known or suspected to be circulating		
Name (First & Last):	Refer to the Committee to Advise on Tropical Medicine and Travel (CATMAT) for recommendations at phac-aspc.gc.ca/tmp-pmv/catmat-		
DOB (YYYY/MM/DD):	ccmtmv/index-eng.php		
	Note: Travellers are eligible to receive a <u>single adult lifetime booster</u> dose of IPV-containing vaccine		
DATE ADMINISTERED:	The most appropriate vaccine (i.e., IPV or Tdap-IPV) should be selected		
HEPATITIS A (AVAXIM®/HAVRIX®)	HR Eligibility – ≥ 1 year with:		
	(please check all that apply)		
Name (First & Last):	☐ Chronic liver disease (including Hepatitis B and C)		
DOD (WWW/MM/DD).	☐ Persons engaging in intravenous drug use		
DOB (YYYY/MM/DD):	☐ Men who have sex with men		
DATE ADMINISTERED:			
Dose # 1 2			



	T	
(please circle dose required)		
HEPATITIS B (RECOMBIVAX HB®/ENGERIX®-B)	HR Eligibility – ≥ 0 years with: (please check all that apply)	
Name (First & Last):	☐ Infant born to HBV-positive carrier mothers:	
DOB (YYYY/MM/DD):	 premature infant weighing <2,000 grams at birth (4 doses) premature infant weighing ≥2,000 grams at birth and full/post term infants (3 doses) 	
DATE ADMINISTERED:	 Household and sexual contacts of chronic carrier and acute case (3 doses) Individuals engaging in intravenous drug use (3 doses) 	
Dose # 1 2 3 4 (please circle dose required) (and boosters if required)	 □ Men who have sex with men (3 doses or 2 doses if 11 – 15 years of age) □ Individual with multiple sex partners (doses according to age) □ History of a sexually transmitted disease (doses according to 	
	age) □ Needle stick injury in a non-health care setting (3 doses) □ Child <7 years old whose family has immigrated from country of high prevalence for hepatitis B and who may be exposed to hepatitis B virus carriers through their extended family (3 doses) □ Chronic liver disease including hepatitis C (3 doses) □ Renal dialysis or disease requiring frequent receipt of blood products (e.g., haemophilia) (2 nd and 3 rd doses only) □ Awaiting liver transplant (2 nd and 3 rd doses only) OR School Program: □ Grade 7 Students (who remain eligible to Grade 12) (2 dose series for those 11 to 15 years and 3 doses for those ≥ 16 years of age)	
Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 (please circle dose required) Please note: Varicella vaccine utilized for routine immunizations may be used for this patient. If Varicella vaccine is not normally stocked, please fill out this form accordingly. The High Risk Immunization Reporting Form must be completed and faxed to Timiskaming Health Unit following vaccine administration.	HR Eligibility those born in or prior to 1999 with: Susceptible children and adolescents given chronic salicylic acid therapy Susceptible individuals with cystic fibrosis Susceptible household contacts of immunocompromised individuals Susceptible individuals receiving low dose steroid therapy or inhaled/topical steroids Susceptible immunocompromised individuals, see the Canadian Immunization Guide	



19.07/4.9.011915	
IMVAMUNE	
IMVAMUNE Name (First & Last): DOB (YYYY/MM/DD): DATE ADMINISTERED: Dose # 1 2 (please circle dose required) (note those with hx of smallpox vaccination should receive only 1 dose of Imvamune)	Eligibility: please check all that apply Two-Spirit, non-binary, transgender, cisgender, intersex, or gender-queer individuals who self-identify or have sexual partners who self-identify as belonging to the gay, bisexual, pansexual and other men who have sex with men (gbMSM) community AND at least one of the following: Had a confirmed sexually transmitted infection (STI) within the last year; Have or are planning to have two or more sexual partners or are in a relationship where at least one of the partners may have other sexual partners; Have attended venues for sexual contact (e.g., bathhouses, sex clubs) recently or may be planning to, or who work/volunteer in these settings; Have had anonymous sex (e.g., using hookup apps) or may be planning to; and/or Are a sexual contact of an individual who engages in sex work.



THU STAFF TO COMPLETE		PAN Req #			
PHU Staff Name and Signature (screening validation completed):					
NAME:	DATE:	SIGNATURE:			
HEALTH CARE PROVIDER PICK UP	Date:	Signature:	_		